This paper aims to understand why prostate cancer with CDK12 loss does not respond to HRd-based therapeutics, such as PARP inhibitors. The work is felt to be fundamental given a thorough computational ...
Total revenues were RMB10.10 billion (US$1.44 billion) for the third quarter of 2024 ... “Through technology-driven cost reductions and significant quarter-over-quarter volume growth, our gross margin ...
Highlights Customers in 27 Counties Now Benefit from Newly Installed Underground Powerlines that Improve Reliability and Eliminate Nearly All Wildfire Risk in a Given Loc. . .